Dariimaa Ganbat1,2, Bat-Erdene Jugder3, Lkhamaa Ganbat4, Miki Tomoeda5, Erdenetsogt Dungubat2,6, Ambaga Miyegombo7, Gantsetseg Garmaa8, Yoshihisa Takahashi6, Ryuji Fukuzawa6, Ichiro Mori6, Takayuki Shiomi6, Akinori Nakata9, Yasuhiko Tomita6,*
Oncologie, Vol.24, No.2, pp. 195-225, 2022, DOI:10.32604/oncologie.2022.022299
Abstract Most cancer cells overexpress the anti-apoptotic protein survivin and display redox dysregulation originating
from genotypic and phenotypic alterations. These disturbances contribute to the uncontrolled proliferation, invasion, and chemoresistance of cancer cells, yet they also represent a specific vulnerability that could be exploited
therapeutically in selected tumors. YM155 (sepantronium bromide) is a naphthoquinone-containing imidazolebased compound that selectively inhibits survivin expression at the transcriptional and post-transcriptional levels.
Here, we performed a systematic review and meta-analysis of clinical studies in which YM155 was administered
as monotherapy or combination therapy for patients with cancer. We assessed fully or partially reported clinical
outcomes and pharmacological… More >
Login
Register
